Cytiva supports the pharmaceutical industry by providing key technologies and tools for cellular and protein research as well as equipment to support the manufacturing of biotherapeutics and cellular therapies. As part of our strategy to further enable life science research, we are actively seeking technologies that can complement our existing intellectual property and accelerate product development within our areas of interest, as further described below.

We support clients with start-to-finish solutions for production of biotherapeutics such as antibodies and vaccines. This includes offerings of cell media and single-use equipment for biopharmaceutical production as well as tools based on chromatography and filtration systems. Total single-use systems and turn-key enterprise solutions are also provided.

We are seeking:

  • Protein expression technologies.
  • Cell culture media.
  • Automation, sensors, and software for process analysis.
  • Chromatography resins and filtration devices for laboratory and manufacturing scale.
  • Affinity ligands.
  • Products and technologies that improve bioproduction processes.

The field of cell therapies has shown rapid growth in the industry over the past few years, driven by dramatic clinical results. With GE’s strength in biomanufacturing, we are well positioned to enable progress in the industry by providing technologies and services to support the entire workflow.

We are seeking:

  • Technologies or techniques along the entire cell therapy workflow, including cell isolation, selection, genetic modification, expansion, downstream processing, and analysis, back into a patient.
  • Overall production scheduling and logistics planning and tracking tools.
  • Opportunities to partner with large pharma in a broader collaboration model.

Our Core Imaging division develops and supplies diagnostic radiopharmaceuticals and contrast media for SPECT, PET, Ultrasound, MR, X-ray, and CT imaging modalities. We provide tracers such as DaTscan™, a SPECT tracer indicated for Parkinson’s disease diagnosis and Vizamyl™, a PET tracer for Alzheimer’s disease diagnosis. In addition, we have a number of imaging agents in development.

We are seeking:

  • Agents that enhance the diagnostic imaging capability of X-ray, CT, MRI, SPECT, and ultrasound imaging modalities.
  • Late stage imaging agents in neurodegeneration, oncology, and cardiology therapy areas.
  • Validated imaging biomarkers to support tracer development.
  • Technologies associated with the use of radiopharmaceuticals and contrast media.

We provide instrumentation, assays, and tools for protein and cellular research to catalyze drug discovery and development. For example, we offer chromatography resins to support antibody and antibody fragment purification, and Biacore systems for label-free protein interaction analysis.

We are seeking:

  • Reagents, consumables, and systems for protein expression, sample preparation, protein purification, identification, and analysis.
  • Protein-protein interaction technologies, such as surface plasmon resonance.

We would be delighted to hear from you if you have a project or product idea in one of the areas of interest listed above. Please only send us non-confidential information at this stage. Read on to learn more about the partnership options we can offer. If you know of an opportunity that may be of interest to us, please email our Licensing Team.